Neos Therapeutics Inc.’s first branded product launch will be delayed as FDA seeks further data to assure that the attention deficit/hyperactivity disorder drug Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets) used in clinical trials is bioequivalent to the commercial product.
The company announced Nov. 10 that it had received a complete response letter from the agency that prevents approval of...